DS
FLGT icon

David Shaw’s Fulgent Genetics FLGT Stock Holding History

David Shaw’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-30,000
Closed -$1.87M – 5461
2022
Q1 		$1.87M Buy
+30,000
New +$1.98M ﹤0.01% 3367
2021
Q2 		– Sell
-20,100
Closed -$1.94M – 4828
2021
Q1 		$1.94M Buy
+20,100
New +$2.07M ﹤0.01% 2617

Other funds holding FLGT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

David Shaw's FLGT Position: Q2 2026 in Review

David Shaw reduced its Fulgent Genetics (FLGT) stake by 40% in Q2 2026, selling an estimated $3.3M and leaving 292,006 shares worth $5.99M. The position accounts for ﹤0.01% of the portfolio, ranked #2257.

David Shaw first reported a position in FLGT in Q1 2021 and has held it in 19 quarters since. The position peaked at $18.4M in Q4 2025. 142 funds tracked by Wall St. Rank hold FLGT as of Q2 2026.

  • David Shaw held 292,006 shares of Fulgent Genetics worth $5.99M as of Q2 2026.
  • David Shaw sold 194,764 Fulgent Genetics shares in Q2 2026, an estimated $3.3M.
  • Fulgent Genetics made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #2257 holding.
  • David Shaw first reported a position in Fulgent Genetics in Q1 2021 and has held it in 19 quarters since.
  • David Shaw's Fulgent Genetics position peaked at $18.4M in Q4 2025.
  • 142 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.